Clinical Trial Update: Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cetuximab in combination with cisplatin for triple-negative metastatic breast cancer has completed, with results posted in October 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• ERBITUX (cetuximab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Breast Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2012-10-10